Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

Investigational New Drugs

Volumn 17, Issue 3, 1999, Pages 195-212

  Zhu, Zhenping ^a   Witte, Larry ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis; Antibody; Cancer therapy; Endothelial cells; Tyrosine kinase receptor; VEGF KDR Flk 1

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 DEDIMETHYLAMINOSANCYCLINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOZYME; ANTINEOPLASTIC AGENT; CGS 27023A; CM 101; FUMAGILLOL CHLOROACETYLCARBAMATE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; MARIMASTAT; MM 1270; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C P1C11; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY LM 609; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; PRINOMASTAT; RITUXIMAB; TANOMASTAT; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR BLOCKING AGENT; VATALANIB; ZK 225846;

ANGIOGENESIS; ANTIBODY PRODUCTION; BIRTH DEFECT; CANCER; CANCER INHIBITION; CLINICAL TRIAL; DRUG SPECIFICITY; GENE TRANSFER; HUMAN; KAPOSI SARCOMA; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033396950     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006314501634     Document Type: Review

References (192)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971
2. Folkman J: What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82: 4-6, 1991
3. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995
4. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424, 1998
5. Weinstat-Saslow D, Steeg PS: Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 8: 401-407, 1994
6. Liotta LA, Steep PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of negative and positive regulation, Cell 64: 327-336, 1991
7. Fidler IT, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994
8. Klagsbrun M, D'Amore PA: Regulators of angiogenesis. Annu Rev Physiol 53: 217-239, 1991
9. Folkman J, Klagsbrun M: Angiogenesis factors. Science 235: 442-447, 1987
10. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989
11. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res & Treat 36: 127-137, 1995
12. Ferrara N: Vascular endothelial growth factor. Trends Cardiovasc Med 3: 244-250, 1993
13. Brown LF, Detmar, M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. In: Goldberg ID, Rosen EM (eds), Regulation of Angiogenesis. Birkhauser Verlag, Basel/Switzerland, 1997, pp 233-269
14. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442, 1996
15. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens K, Gertsenstein M, Farhig M, Vandenhoeck A, Harpal K, Eberhardt C, Deciercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996
16. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breltman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66, 1995
17. Shalaby F, Ho J, Stanford WL, Klaus-Dieter F, Schuh AC, Schwartz L, Bernstein A, Rossant J: A requirement for Flk1 in primitive and definitive hematopoicsis and vasculogenesis. Cell 89: 981-990, 1997
18. Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995
19. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994
20. Kim J, Li B, Winer J, Armanini M, Gillett N, Phillip HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993
21. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusening NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3: 1222-1227, 1997
22. Pluda JM: Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semi Oncol 24: 203-218, 1997
23. Gradishar W: An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Invest New Drugs 15: 49-59, 1997
24. Wolfe MS: Angiogenesis. IDrugs 1: 22-25, 1998
25. Klagsbrun M, D'Amore PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7: 259-270, 1996
26. Maglione D, Guerriero V, Viglietto G, Delli Bovi P, Persico MG: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88: 9267-9271, 1991
27. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93: 2576-2581, 1996
28. Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122: 3829-3837, 1996
29. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinase VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95: 548-553, 1998
30. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806-1814, 1991
31. Tischer E, Mitchell R, Hartmann T, Silva M, Gospodarowicz D, Fiddes J, Abraham J: The human gene for vascular endothelial growth factor. J Biol Chem 266: 11947-11954, 1991
32. Keyt BA, Berleau LT, Nguyen HV, Chen C, Heinsohn H, Vandlen R, Ferrera N: The carboxy-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271: 7788-7795, 1996
33. Houck KA, Leung DW, Rowland AM, Winer J, Ferrera N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267: 26031-26037, 1992
34. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen C, Ferrera N: Identification of vascular endothelial growth factor determinants for binding KDR and Flt-1 receptors. J Biol Chem 271: 5638-5646, 1996
35. Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H, Klagbrun M: Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem 272: 31582-31588, 1997
36. DiSalvo J, Bayne ML, Conn G, Kwok, PW, Trivedi, PG, Soderman, DD, Palisi, TM, Sullivan KA, Thomas, KA: Purification and characterization of a naturally occurring vascular endothelial growth factor/placenta growth factor heterodimer. J Biol Chem 270: 7717-7723, 1995
37. Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang MLS: Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 271: 3154-3162, 1996
38. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K: Protoeolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16: 3898-3911, 1997
39. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Sxxx M, Fukumura D, Jain RK, Alitalo K: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276: 1423-1425, 1997
40. Oh SJ, Jeltsch MM, Birkenhager R, McCarthy JEG, Weich HA, Christ B, Alitalo K, Wilting J: VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 188: 96-109, 1997
41. Joukov V, Pajusola K, Paipainen, A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 290-298, 1996
42. Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI: Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93: 1988-1992, 1996
43. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S: Identification of a c-fos-induced gene that is related to the platelet-derived, growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA 93: 11675-11680, 1996
44. Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K: Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol 177: 439-452, 1998
45. Lyttle DJ, Fraser KM, Flemings SE, Mercer AA, Robinson AJ: Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J Virol 68: 84-92, 1994
46. Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M: A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 273: 31273-31282, 1998
47. Wise LM, Veikkola T, Mercer AA, Savory LJ, Fleming SE, Caesar C, Vitali A, Makinen T, Alitalo K, Stacker SA: Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc Natl Acad Sci USA 96: 3071-3076, 1999
48. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt-1) closely related to the fms family. Oncogene 5: 519-524, 1990
49. De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992
50. Terman BI, Dougher-Vermazen M, Carrion ME, Dimtrov D, Armellino DC, Gospodarowicz D, Bohlen P: Identification of the KDR tyrosine kinase receptor as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 187: 1579-1586, 1992
51. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NPH, Risau W, Ullrich A: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846, 1993
52. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT: Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90: 7533-7537, 1993
53. Peters KG, De Vries C, Williams LT: Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci USA 90: 8915-8919, 1993
54. Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, Alitalo K: FLT-4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res 52: 5738-5743, 1992
55. Galland F, Karamysheva A, Pebusque MJ, Borg JP, Rottapel R, Dubreuil P, Posnet O, Birnbaum D: The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 8: 1233-1240, 1993
56. Soker S, Fidder H, Neufeld G, Klagsbrun M: Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 271: 5761-5767, 1996
57. Soker S, Takashima S, Miao HQ, Neufeld, Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745, 1998
58. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995, 1994
59. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi M, Shibuya M: A unique signal transduction pathway for the FLT tyrosine kinase, a receptor for vascular endothelial growth factor. Oncogene 10: 135-137, 1995
60. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D: Migrrttion of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343, 1996
61. Clauss M, Weich HA, Breier G, Knies U, Rockl W, Waltenberger J, Risau W: The vascular endolhelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271: 17629-17634, 1996
62. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95: 9349-9354, 1998
63. Kendall RL, Thomas KA: Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci 90: 10705-10709, 1993
64. Goldman CK, Kendall RL, Cabrera G, Sorocaenu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomao KA, Curiel DT: Paracrine expression of a native soluble vascular growth factor receptor inhibits tumor growth, metasta4is, and mortality rate. Proc Natl Acad Sci USA 95: 8795-8800, 1998
65. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR: A receptor tyrosine cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 88: 9026-9030, 1991
66. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM: Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 94: 7192-7197, 1997
67. Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marmé D, Martiny-Baron G: Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272: 10382-10388, 1997
68. Fuh G, Li B, Crowley C, Cunningham B, Wells JA: Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor, J Biol Chem 273: 11197-11204, 1998
69. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM: Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91, 695-704, 1997
70. Kaplan JB, Sridharan L, Zaccardi JA, Dougher-Vermazen M, Terman BI: Characterization of a soluble vascular endothelial growth factor receptor-immunoglobulin chimera. Growth Factors 14: 243-256, 1997
71. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M: Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 273: 31282-31288, 1998
72. Shinkai A, Ito M, Anazawa H, Yamaguchi S, Shitara K, Shibuya M: Mapping of the site involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 273: 31282-31288, 1998
73. Cunningham SA, Stephan CC, Arrate PM, Ayer KG, Brock TA: Identification of the extracellular domains of Flt-1 that mediate ligand interactions. Biochem and Biophys Res Commun 231: 596-599, 1997
74. Davis-Smith T, Presta LG, Ferrara N: Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability. J Biol Chem 273: 3216-3222, 1998
75. Davis-Smyth T, Chen H, Park J, Presta LG, Ferrara N: The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 15: 4919-4927, 1996
76. Park JE, Chen HH, Winer J, Houck KA, Ferrara N: Placenta growth factor. Potentiation of vascular growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 269: 25646-25654, 1994
77. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990
78. Merenmies J, Parada LF, Henkemeyer M: Receptor tyrosine kinases signaling in vascular development. Cell Growth Diff 8: 3-10, 1997
79. Fanti WJ, Escobedo JA, Martin GA, Turck CW, del Rosario M, McCormick F, Williams LT: Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 69: 413-423, 1992
80. Valius M, Kazlauskas A: Phosholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 73: 321-334, 1993
81. Heldin CH: Dimerization of cell surface receptors in signal transduction. Cell 80: 213-223, 1995
82. Dougher-Vermazen M, Hulmes JD, Bohlen P, Terman BI: Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem Biophys Res Commun 205: 728-738, 1994
83. Ito N, Wernstedt C, Engström, Claesson-Welsh L: Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J Biol Chem 273: 23410-23418, 1998
84. Guo D, Jia Q, Song HY, Warren RS, Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains Association with endothelial cell proliferation. J Biol Chem 270: 6729-6733, 1995
85. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/akt signal transduction pathway. J Biol Chem 273: 30336-30343, 1998
86. Abedi H, Zachary I: Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelialcells. J Biol Chem 274: 15442-15451, 1997
87. Kroll J, Waltenberger J: The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272: 32521-32527, 1997
88. Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, Pelicci PG, Birnbaum D, Borg JP: Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase. J Biol Chem 271: 12956-12963, 1996
89. Takahashi T, Shibuya M: The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 20: 2079-2089, 1997
90. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735, 1993
91. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Path 26: 86-91, 1995
92. Guidi A, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87: 1237-1245, 1995
93. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR: Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143: 1255-1262, 1993
94. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54: 276-280, 1994
95. Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF, Brown LF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 78: 454-460, 1996
96. Brown LF, Tognazzi K, Dvorak H, Harrist T: Strong expression of KDR, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 148: 1065-1074, 1995
97. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human glioma in vivo. Nature 359: 845-848, 1992
98. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH: Expression of vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91: 153-159, 1993
99. Wizigmann-Voos S, Breier G, Risau W, Plate KH: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358-1364, 1995
100. Bellamy WT, Richter L, Frutiger Y, Grogan TM: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59: 28-733, 1999
101. Weidner N, Semple P, Welch W, Folkman J: Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med 324: 1-6, 1991
102. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW: Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87: 1603-1612, 1995
103. Bigler SA, Deering RE, Brawer MK: Comparison of microscopic vascularity in benign and malignant prostatic tissue. Human Pathol 24: 220-226, 1993
104. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, Radaelli U, Di Bacco A, Guglielmi RE, Bevilacqua P: Prognostic and predictive value of tumor angiogenesis in ovarian carcinomas. Int J Cancer 69: 205-211, 1996
105. Lindmark G, Gerdin B, Sundberg C Pahlman L, Bergstrom R, Glimelius B: Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol 14: 461-466, 1996
106. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, Iki M: Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinoma. Cancer Res 56: 2671-2676, 1996,
107. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA: Relation of neovascularisation to metastasis of non-small cell lung cancer. Lancet 340: 145-146, 1992
108. Sillman F, Boyce J, Fruchter R: The significance of atypical vessels and neovascularization in cervical neoplasias. Am J Obstet Gynecol 139: 154-157, 1981
109. Barnhill RL, Fandrey K, Levy MA, Mihm MC Jr., Hyman B : Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 67: 331-337, 1992
110. Olivarez D, Ulbright T, DeRiese W, Foster R, Reister T, Einhorn L, Sledge G: Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 54: 2800-2802, 1994
111. Gasparini G, Weidner N, Maluta S Pozza F, Boracchi P, Mezzetti M, Testolin A, Bevilacqua P: Intratumoral microvessel density and p53 protein: correlation with metastasis in head- and neck squamous-cell carcinomas. Int J Cancer 57: 739-744, 1993
112. Li VW, Folkerth RD, Watanabe H, Yu C, RupnickM, Barnes P, Scott RM, Black PM, Sallan SE, Folkman J: Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 344: 82-86, 1994
113. Plate KH, Breier G, Millauer B, Ullrich A, Risau W: Upregulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53: 5822-5827, 1993
114. Zhang HT, Craft P, Scott PA, Ziehe M, Weich HA, Harris AL, Bicknell R: Enhancement of tumor growth and vascular density by transfection of vascular endothelial growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 87: 213-219, 1995
115. Ferrara N, Winer J, Burton T, Rowland A, Siegel M, Phillips HS, Terrell T, Keller GA, Levinson AD: Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J Clin Invest 91: 160-170, 1993
116. Rockwell P, Neufeld G, Glassman A, Caron D, and Goldstein N: in vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody. Mol Cell Differ 3: 91-109, 1995
117. Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ, Bohlen P, Witte L: Inhibition of vascular endothelial growth factor induced receptor activation with antikinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 58: 3209-3214, 1998
118. Zhu Z, Lu D, Kotanides H, Santiago A, Jimenea X, Sim-cox T, Hicklin DJ, Bohlen P, Witte L: Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-KDR receptor antibody. Cancer Lett 1999, in press
119. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56: 393-401, 1996.
120. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D: Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/Flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56: 1324-1330, 1996
121. Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS: Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 59: 183-188, 1999
122. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Diff 9: 49-58, 1998
123. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang, C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK: Flk-1 as a target for tumor growth inhibition. Cancer Res 56: 3540-3545, 1996
124. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell JT, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth PK, McMahon G: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106, 1999
125. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997
126. Kerbel RS: A cancer therapy resistant to resistance (News and Views). Nature 390: 335-336, 1997
127. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P: Monoclonal antibodies targeting the VEGF receptor-2 (Flk-1/KDR) as an anti-angiogenic therapeutic strategy, Cancer Met Rev 17: 155-161, 1998
128. Brekken RA, Huang X, King SW, Thorpe PE: Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 58: 1952-1959, 1998
129. Presta L, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599, 1997
130. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571, 1994
131. Rockwell P, Goldstein N: Role of protein tyrosine kinase receptors in cancer: possibilities for therapeutic intervention. Mole Cell Diff 3: 315-335, 1995
132. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA: Antiintegrin blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-1822, 1995
133. Juhasz I, Albelda SM, Elder DE, Murphys GF, Adachi K, Herlyn D, Valyi-Nagy IT, Herlyn M: Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Path 143: 528-531, 1993
134. Kusaka S, Hicklin DJ, Witte I, Bohlen P, Burlingham WJ: Effect of anti-VEGF receptor monoclonal antibodies on tumor growth and angiogenesis in SCID mouse/human skin graft model (Abstract). Amer Asso for Cancer Res 40: 68, 1999
135. Hawkins MJ: Clinical trials of antiangiogenic agents. Curr Opin Oncol 7: 90-93, 1995
136. Ogilvie DJ: ZD4190: an inhibitor of signal tranduction with anti-tumor activity. In: Angiogenesis: Novel Therapeutic Development. IBC Fifth Annual International Conference. Boston, MA, 1999
137. Sandberg JA: Pharmacology and toxicity of an antiangiogenic ribozyme. In: Angiogenesis: Novel Therapeutic Development. IBC Fifth Annual International Conference. Boston, MA, 1999
138. Neri D, Carnemolla B, Nissim A, Leprini A, Querzè G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G: Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15: 1271-1275, 1997
139. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D: Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 59: 347-353, 1999
140. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275: 547-550, 1997
141. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK: Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vascular using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 5: 371-382, 1999
142. Spragg DD, Alford DR, Greferath R, Larsen CE, Lee KD, Gurtner GC, Cybulsky MI, Tosi PF, Nicolau C, Gimbrone MA: Immunotargeting ofliposomes to activated vascular endothelial cells: A strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA 94: 8795-8800, 1997
143. Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380, 1998
144. Piccoli R, Olson KA, Vallee BL, Fett JW: Chimeric antiangiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. Proc Natl Acad Sci USA 95: 4579-4583, 1998
145. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG: Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA 95: 8829-8834, 1998
146. Siemeister G, Schirner M, Reusch P, Barleon B, Marmé D, Martiny-Baron G: An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc Natl Acad Sci USA 95: 4625-4629, 1998
147. Powell WC, Matrisian LM: Complex roles of matrix metalloproteinases in tumor progression. Curr Top Microbiol Immunol 213: 1-21, 1996
148. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 555-557, 1990.
149. Kusaka M, Sudo K, Fujita T: Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent. Biochem Biophys Res Commun 174: 1070-1076, 1991
150. Berm H, Folkman J: Analysis of experimental antiangiogenic therapy. J Fed Surg 28: 445-451, 1993
151. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM: The antiangiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94: 6099-6103, 1997
152. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994
153. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87: 581-586, 1995
154. Stricter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ: Interferon gamma-inducible protien 10 (IP-IO), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 201: 51-57, 1995
155. Sgadari C, Angiolillo AL, Tosato G: Inhibition of angiogenesis by interleukin 12 is mediated by the interferon-inducible protein 10. Blood 87: 3877-3882, 1996
156. Hellerqvist CG, Thurman GB, Page DL, Wang YF, Russel BA, Montgomery CA, Sundell HW: Anti-tumor effects of GBS toxin: a polysaccharide exotoxin from group B b-hemolytic streptococcus. J Cancer Res Clin Oncol 120: 63-70, 1993
157. Yan H, Carter CE, Wang E, Page DL, Washington K, Wamil ED, Yakes FM, Thurman GB, Hellerqvist CG: Functional studies on the anti-pathoangiogenic properties of CMIOI. Angiogenesis 2: 219-233, 1999
158. Thurman GB, Russel BA, York GE, Wang YF, Page DL, Sundell HW, Hellerqvist CG: Effects of GBS toxin on long term survival of mice bearing transplanted Madison lung tumors. J Cancer Res Clin Oncol 120: 479-484, 1994
159. DeVore RF, Hellerqvist CG, Wakefield, ED, Wamil ED, Thurman GB, Minton PA, Sundell HW, Yan HP, Carter CE, Wang YF, York GE, Zhang MH, Johnson DH: A phase I study of the anti-neovascularization drug CM101. J Clin Cancer Res 3: 365-372, 1997
160. Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56: 569-573, 1996
161. Sills AK Jr, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zasloff M, Brem H: Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 58: 2784-1792, 1998
162. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell 79: 315-328, 1994
163. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997
164. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689-692, 1996
165. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M, Sukhatme VP: Endostatin: Yeast production, mutants, and antitumor effects in renal cell carcinoma. Cancer Res 59: 189-197, 1999
166. Wu Z, O'Reilly MS, Folkman J, Shing Y: Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 236: 651-654, 1997
167. Tanaka T, Cao Y, Folkman J, Fine HA: Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 58: 3362-3369, 1998
168. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, Perricaudet M, Yeh P, Lu H: Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 95: 6367-6372, 1998
169. Lucas R, Holmgren L, Jimenez B, Mandrota SJ, Borlat F, Sim BK, Wu Z, Grau GE, Shing Y, Soff GA, Bouck N, Pepper MS: Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92: 4730-4741, 1998
170. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, O'Reilly M, Folkman J: Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RCD. Proc Natl Acad Sci USA 95: 5579-5583, 1998
171. Hohenester E, Sasaki T, Olsen BR, Timpl R: Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 17: 1656-1664, 1998
172. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, William Schnaper H, Pizzo SV: Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96: 2811-2816, 1999
173. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE: Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 82: 848-853, 1990
174. Volpert OV, Lawler J, Bouck NP: A human fibrosarcoma inhibits systemic angigenesis and the growth of experimental metastasis via thrombospondin-1. Proc Natl Acad Sci USA 95: 6343-6348, 1998
175. D'Angelo G, Struman I, Martial J, Weiner RI: Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells in inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 92: 6374-6378, 1995
176. Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP: Inhibition of angiogenesis by interleukin 4. J Exp Med 188: 1039-1046, 1998
177. Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, Flynn E, Sytkowski A, Tao T, Langer R: TroponinI is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci USA 96: 2645-2650, 1999
178. Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160: 194-202, 1994
179. Aiello LP, Avery R, Arrigg PG, Keyt B, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen MS, Aiello LM, Ferrara N: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487, 1994
180. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E: Hypoxia-induced expression of vascular endothelial growth factor (VEGF) by retinal cells is a common factor in neovascularization. Lab Invest 72: 638-645, 1995
181. Adamis AP, Shima DT, Tolentino M, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW: Inhibition of VEGF prevents occular neovascularization in a primate. Arch Ophthalmol 114: 66-71, 1996
182. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 12: 10457-10461, 1995
183. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N: Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152: 4149-4156, 1994
184. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF: Vascular permeability factor / vascular endothelial growth factor (VPFNEGF): accumulation and expression in human synovial fluids and rheumatoid arthritis. J Exp Med 180: 340-346, 1994
185. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180: 1141-1146, 1994
186. Brown LF, Harris TJ, Yeo KT, Stahle-Backdahl M, Jackman RW, Berse B, Tognazzi K, Dvorak HF, Detmar M: Increased expression of vascular permaebility factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiforme, and erythema multiforme. J Invest Dermatol 104: 744-749, 1995
187. Teicher BA, Sotomayor EA, Huang ZD: Anriangiogenic agents potentiate cytotoxic cancer therapies against primary and metastasis disease. Cancer Res 52: 6702-6704, 1992
188. Teicher BA, Holden SA, Ara G, Korbut T, Memon K: Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 38: 169-177, 1996
189. Anderson IC, Shipp MA, Docherty AJ, Teicher BA: Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res 56: 715-718, 1996
190. Sotomayor EA, Teicher BA, Schwartz GN, Holden SA, Memon K, Herman TS, Frei E: Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 30: 377-384, 1992
191. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR: Potentiation of the antirumor effect of ionzing radiation by brief concomitant exposures to angiostarin. Cancer Res 58: 5686-5689, 1998
192. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Stabs MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-291, 1998